Cover Image
市場調查報告書

中國的Enoxaparin Sodium市場分析

Investigation Report on China Enoxaparin Sodium Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 296865
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Enoxaparin Sodium市場分析 Investigation Report on China Enoxaparin Sodium Market, 2009-2018
出版日期: 2014年02月28日 內容資訊: 英文 40 Pages
簡介

血栓症,是在血管內形成血栓(血塊),妨礙血流通過循環系統。全球每年有1,200萬人,由於腦血栓症、中風、心肌梗塞、冠狀動脈心臟病、動脈硬化等,心血管、腦血管疾病死亡。中國的心血管疾病發病率持續增加。目前心血管疾病的患者數,成人10人有2人,推定大概有2億9,000萬人。Enoxaparin Sodium是Aventis公司(後與Sanofi公司合併)開發的低分子量肝素。

本報告提供中國的Enoxaparin Sodium市場相關調查分析、血栓症的發病率、主要廠商的市場佔有率、醫院市場上的銷售價格、學名藥的生產情形、主要製造商簡介、市場預測等,為您概述為以下內容。

第1章 Enoxaparin Sodium的相關概念

  • 適應和開發過程
  • 全球市場銷售情形
  • 主要製造商

第2章 中國的Enoxaparin Sodium的市場概要

  • 專利狀況
  • 學名藥的生產情形
  • 主要製造商
  • 市場規模

第3章 中國的Enoxaparin Sodium的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Enoxaparin Sodium的主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售量

第5章 中國的Enoxaparin Sodium(各劑型)的市場規模分析

  • 市場佔有率:各銷售額、劑型
  • 市場佔有率:各銷售量、劑型

第6章 中國的醫院市場上Enoxaparin Sodium的標準價格(各企業)

  • Sanofi
  • Sanofi Winthrop Industrie S.A.
  • Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
  • Hangzhou Jiuyuan Gene Engineering Co., Ltd.

第7章 中國的Enoxaparin Sodium的主要製造商分析

  • Sanofi
  • Sanofi Winthrop Industrie S.A.
  • Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
  • Hangzhou Jiuyuan Gene Engineering Co., Ltd.

第8章 中國的Enoxaparin Sodium市場預測

  • 中國的血栓症的發病率預測
  • 學名藥的研究情形
  • 市場規模的預測
  • 市場競爭的預測

圖表

目錄
Product Code: 1402117

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.

Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name "Lovenox". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.

Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.

Four manufacturers in China have received production approval of enoxaparin sodium injection by early 2014. According to CRI's market investigation, products of Sanofi and its related enterprises occupy most market share in Chinese sample hospitals, followed by Hangzhou Jiuyuan Gene Engineering Co., Ltd.

The CAGR of sales value of enoxaparin sodium injection in Chinese sample hospitals exceeded 17% from 2005 to 2012. On the one hand, incidence of vascular embolism keeps rising due to population aging in China. On the other hand, operations such as cardiovascular and cerebrovascular intervention develop rapidly. Followed up by the development of anticoagulation, antiplatelet and hypolipidemic treatment after stent surgery, antithrombotic drug market has been greatly expanded in China.

It is estimated that enoxaparin sodium market in China will rise significantly in the next few years.

Through this report, the readers can acquire the following information:

  • Incidence of Thrombosis in China
  • Market Share of Major Enoxaparin Sodium Manufacturers in China Sample Hospitals
  • Sales price of Enoxaparin Sodium in China Hospital Market
  • Production Status of Enoxaparin Sodium Generic Drug in China
  • Major Enoxaparin Sodium Manufacturers in China
  • Prospect of China Enoxaparin Sodium Market

The following enterprises and people are recommended to purchase this report:

  • Anti-clotting Drugs Manufacturers
  • Medical Institutions
  • Investors /Research Agencies Focusing on Anti-clotting Drug Market

Table of Contents

1. Relevant Concepts of Enoxaparin Sodium

  • 1.1. Indications and Development Process
  • 1.2. Sales Status on the Global Market
  • 1.3. Major Manufacturers

2. Market Overview of Enoxaparin Sodium in China

  • 2.1. Patent Status
  • 2.2. Production Status of Generic Drug
  • 2.3. Major Manufacturers
  • 2.4. Market Size

3. Investigation on Sales Value of Enoxaparin Sodium in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Enoxaparin Sodium Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Enoxaparin Sodium by Dosage Form in China, 2009-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Enoxaparin Sodium Produced by Different Enterprises in China Hospital Market, 2014

  • 6.1. Sanofi
  • 6.2. Sanofi Winthrop Industrie S.A.
  • 6.3. Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
  • 6.4. Hangzhou Jiuyuan Gene Engineering Co., Ltd.

7. Analysis on Major Enoxaparin Sodium Manufacturers in China, 2014

  • 7.1. Sanofi
  • 7.2. Sanofi Winthrop Industrie S.A.
  • 7.3. Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
  • 7.4. Hangzhou Jiuyuan Gene Engineering Co., Ltd.

8. Prospect of China Enoxaparin Sodium Market, 2014-2018

  • 8.1. Prediction of Thrombosis Incidence in China
  • 8.2. Research Status of Generic Drug
  • 8.3. Forecast on Market Size
  • 8.4. Forecast on Market Competition

Selected Charts

  • Chart Enoxaparin Sodium Products Approved to Market in China by 2014
  • Chart Sales Value of Enoxaparin Sodium in Global Market, 2009-2013
  • Chart Sales Value of Enoxaparin Sodium in China Sample Hospital Market, 2009-2013
  • Chart Sales Value of Enoxaparin Sodium by Region in China, 2009-2013
  • Chart Market Share of Enoxaparin Sodium Enterprises by Sales Value in China, 2009-2013
  • Chart Price of Enoxaparin Sodium Produced by Sanofi in China Hospital Market, 2014
  • Chart Price of Enoxaparin Sodium Produced by Hangzhou Jiuyuan Gene Engineering Co., Ltd. in China Hospital Market, 2014
  • Chart Forecast on Market Size of Hospital-use Enoxaparin Sodium in China, 2014-2018
Back to Top